Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
Retrieved on:
Thursday, June 8, 2023
BSE, APG system, Plaque, Arthritis, Icahn School of Medicine at Mount Sinai, Physician, Stroke, NYU, Cancer, New York University Grossman School of Medicine, Type 2 diabetes, Woman, Research, Alzheimer's disease, Artery, Inflammation, Cell, Doctor of Philosophy, National Institutes of Health, Atherosclerosis, Bangladesh Technical Education Board, Lung, MS, Saracatinib, Blood, NYU Langone Health, Plasma, Protein, Patent, Patient, Pathology, Rabbit, Kent, Mouse, ASCVD, Moyamoya disease, Cytokine, Integration, Gene, NIH, Safety, Disease, Pharmaceutical industry, Vaccine, Medicine, MD
NEW YORK, June 8, 2023 /PRNewswire/ -- An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer's disease may slow the progression of atherosclerosis that leads to heart disease, a new study shows.
Key Points:
- NEW YORK, June 8, 2023 /PRNewswire/ -- An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer's disease may slow the progression of atherosclerosis that leads to heart disease, a new study shows.
- As this buildup hardens into plaques and causes misplaced immune reactions (inflammation), it can block blood flow to cause heart attack or stroke.
- Further experiments then showed that the drug saracatinib reduced this inflammation signaling by more than 90% in human blood samples and diseased tissue samples.
- Physicians prescribe statins to reduce harmful fats in the blood, but studies show that even with reduced plaque deposits, inflammation persists in many patients, who remain at high risk for heart attack.